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Abstract: Since the advent of highly active antiretroviral therapy (HAART), the treatment of 
human immunodeficiency virus (HIV) infection has become more potent and better tolerated. 
While the current treatment regimens still have limitations, they are more effective, more conve-
nient, and less toxic than regimens used in the early HAART era, and new agents, formulations 
and strategies continue to be developed. Simplification of therapy is an option for many patients 
currently being treated with antiretroviral therapy (ART). The main goals are to reduce pill 
burden, improve quality of life and enhance medication adherence, while minimizing short- and 
long-term toxicities, reducing the risk of virologic failure and maximizing cost-effectiveness. 
ART simplification strategies that are currently used or are under study include the use of 
once-daily regimens, less toxic drugs, fixed-dose coformulations and induction-maintenance 
approaches. Improved adherence and persistence have been observed with the adoption of some 
of these strategies. The role of regimen simplification has implications not only for individual 
patients, but also for health care policy. With increased interest in ART regimen simplifica-
tion, it is critical to study not only implications for individual tolerability, toxicity, adherence, 
persistence and virologic efficacy, but also cost, scalability, and potential for dissemination and 
implementation, such that limited human and financial resources are optimally allocated for 
maximal efficiency, coverage and sustainability of global HIV/AIDS treatment.
Keywords: ART, simplification, adherence, persistence, once-daily, coformulations, healthcare 
cost, quality of life
Introduction
Since the advent of highly active antiretroviral therapy (HAART), the treatment of 
human immunodeficiency virus (HIV) infection has become more potent and better 
tolerated. While the current treatment regimens still have limitations, they are more 
effective, more convenient, and less toxic than regimens used in the early HAART 
era, and new agents, formulations and strategies continue to be developed.1
Simplification of therapy is an option for many patients currently being treated 
with antiretroviral therapy (ART). The main goals are to reduce pill burden and to 
improve quality of life and medication adherence, while minimizing short- and long-
term toxicities, reducing the risk of virologic failure, preserving future treatment 
options, maximizing cost-effectiveness and ultimately reducing the occurrence of 
clinical events and disease progression.1
ART simplification strategies that have been used or are under study include the 
use of fixed-dose combinations, adoption of once-daily regimens with less toxic drugs, 
and more recent induction-maintenance approaches.1,2 Intermittent ART strategies, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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previously felt to be promising approaches for treatment 
simplification, have now been discredited in clinical trials.
In this article, we review the major aspects of these simplifi-
cation strategies and discuss their ability to improve ART adher-
ence and persistence, clinical outcomes, toxicity and quality of 
life as well as the potential impact on healthcare costs.
Methods
We retrieved published English language studies via PubMed, 
Medline and Google Scholar through January 2011. Our 
search terms included “HIV”, “treatment simplification”; 
“adherence”; “HAART”; “ART”; “cART”; “patient prefer-
ence”; “healthcare cost”. Abstracts from major HIV/AIDS 
or infectious diseases conferences such as Conference on 
Retrovirus and Opportunistic Infections (CROI), Interna-
tional AIDS Society (IAS), International AIDS Conference, 
International Conference on Antimicrobials Agents and 
Chemotherapy (ICAAC) and Infectious Diseases Society of 
America (IDSA) were also reviewed for inclusion.
Fixed-dose combinations  
and once-daily regimens
Fixed-dose combinations  
or coformulations
Fixed-dose combinations or coformulations (FDCs) are 
products that combine two or more active drugs in one tablet 
or capsule. There are many potential advantages and disad-
vantages of FDCs (Table 1). A reduction in pill burden has 
been associated with improved ART adherence (Figure 1). 
Possible limitations include the lack of pediatric equivalents, 
inadequate provision for lead-in dosing and a number of other 
shortcomings concerning availability, packaging and   provision 
for reporting adverse events (Table 1). As an example, the 
three-drug, single tablet coformulation of tenofovir disoproxil 
fumarate (TDF), emtricitabine (FTC) and efavirenz (EFV) 
is approved for once-daily dosing in the US and is the first 
available fixed-dose combination tablet containing all compo-
nents of a preferred antiretroviral regimen (Table 2). Several 
generic pharmaceutical manufacturers produce low priced 
FDCs for once- or twice-daily dosing3. Questions have been 
raised about the bioequivalence of such generic formulations, 
but so far published clinical trial data have been reassur-
ing, and these generic FDCs are being approved by the US 
FDA for use in President’s Emergency Plan for AIDS relief 
(PEPFAR) programs in resource-limited settings.4,5
Once-daily regimens and impact on 
treatment adherence and persistence
Parienti and colleagues investigated treatment adherence with 
once-daily regimens, assessing 11 randomized,   controlled 
Table 1 Avantages and disadvantages of fixed-doses combinations 
(FDCs)
Advantages of FDCs
Decreased pill burden
Better adherence
Prescription errors less likely
Patients unable to take partial regimen
experience of FDCs with other diseases such as tuberculosis, malaria etc
Practical for management in large programs (improved drug supply systems)
Cheaper in generic form (eg, in resource-limited settings)
Disadvantages of FDCs
Does not accommodate lead-in dose
Difficult to use when dose adjustments are needed (eg, renal failure)
Need to stop FDC for adverse drug reaction to one component
Limited availability of pediatric formulations
More expensive if generic version of one or more components available  
(developed countries)
Table 2 Approved and under study antiretroviral therapy cofor-
mulations
Type
Approved coformulations
AZT/3TC Dual NRTi
d4T/3TC Dual NRTi
ABC/3TC* Dual NRTi
TDF/FTC* Dual NRTi
TDF/FTC/eFV* Dual NRTi + NNRTi
TDF/3TC/eFV Dual NRTi + NNRTi
AZT/3TC/NVP Dual NRTi + NNRTi
d4T/3TC/NVP Dual NRTi + NNRTi
AZT/3TC/ABC* Triple NRTi
LPV/r* Boosted Pi
Coformulations under study
TDF/FTC/rilpivirine Dual NRTi + NNRTi
TDF/FTC/elvitegravir/cobicistat Dual NRTi + boosted integrase inhibitor
Note: *Available in United States.
Abbreviations: AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ABC, abacavir; 
TDF,  tenofovir  disoproxil  fumarate;  FTC,  emtricitabine;  EFV,  efavirenz;  LPV/r, 
lopinavir/ritonavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Figure 1 1996 to 2011, from multiple drugs to once-daily and more potent antiret-
roviral therapy regimens: the long road to patient satisfaction and adherence.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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trials with a total of 3029 subjects.6 In this meta-analysis, 
adherence rates were modestly better with once-daily 
  regimens (+2.9%; 95% confidence interval (CI), 1.0%–4.8%; 
P , 0.003) than with twice-daily regimens. The effect size 
was more pronounced for ART-naïve patients and when all 
medications were taken once daily. Of note, 48-week   virologic 
suppression with once- and twice-daily regimens was similar 
(77% versus 76%, respectively). More recent studies compar-
ing once-daily regimens to more frequently dosed regimens 
continue to support the positive impact of once-daily regi-
mens on ART adherence (Table 3).   Maitland and colleagues 
performed a randomized trial in which patients were switched 
from abacavir (ABC) plus lamivudine (3TC) BID to a QD 
fixed-dose formulation of ABC/3TC and demonstrated that 
an all-QD regimen improved multiple measures of adherence 
(via MEMScap) and patient satisfaction (measured by HIV 
treatment satisfaction questionnaire [HIVSTQ] score) with 
treatment over 4 and 8 weeks of follow-up.7 A randomized 
controlled trial by Wright and colleagues evaluating safety 
and antiviral activity of QD versus BID enfuvirtide docu-
mented better adherence (95% versus 80%) of prescribed 
doses with the once-daily strategy.8 In another randomized 
trial, 320 patients with viral load , 50 copies/mL on ART 
regimens dosed at least twice-daily were randomized to 
switch to a once-daily regimen (EFV, extended-release 
stavudine [d4TxR], and 3TC) or to continue existing thera-
py.9 Adherence was monitored using MEMS caps, an AIDS 
Clinical Trials Group (ACTG)-validated questionnaire, and 
pill counts. By the primary efficacy measure (proportion of 
patients who maintained virologic suppression at Week 48), 
the once-daily arm was non inferior (80.0%) to the twice-
daily arm (75.8%), and 91.0% of patients preferred the 
simpler regimen.9
Following US FDA approval in 2009 of lopinavir/ 
ritonavir (LPV/r) tablets for once daily use in   treatment-  naïve 
patients, the results of the M06-802 trial became   available.10 
In this study, 599 patients failing ART with a viral 
load . 1000 copies/mL were randomized 1:1 to taking LPV/r 
once daily or twice daily, both arms at a total daily dose of 
800/200 mg. Trial participants had to be naïve to LPV/r and 
the choice as to the background regimen was made by the 
treating investigator, who had genotyping testing available. 
The   once-daily arm was found to be non-inferior in terms 
of   efficacy, and toxicity, notably diarrhea, was not more 
frequent in the once-daily arm. Non-inferiority for efficacy 
could not be evaluated for patients with 3 or more significant 
protease inhibitor (PI) mutations, as only 27 such subjects 
participated. Treatment adherence was significantly better 
for the once-daily arm. Although pill burden is unchanged 
by once-daily adminstration of LPV/r, this does provide an 
opportunity of simplifying regimen in countries with limited 
choice of PI; in many cases it is the only one offered on 
treatment programs. The FDA approved once daily admin-
istration of LPV/r in treatment experienced persons in 2010, 
but does not recommend once daily dosing for adult patients 
with three or more LPV resistance-associated substitutions: 
L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, 
I54L/T/V , V82A/C/F/S/T, and I84V .10
Once-daily, fixed-dose regimens are also attractive for 
difficult-to-treat patients, such as injecting drug users and 
the homeless and other marginally housed HIV-infected indi-
viduals. To address this question, the single-tablet regimen 
of TDF/FTC/EFV was compared to regimens taken more 
than once daily.11 Adherence was significantly higher with 
the single-tablet regimen (P = 0.006), with better viral sup-
pression (HIV RNA , 50 copies/mL: 69.2% versus 46.5%; 
P = 0.02) Finally, using a mixed effect model, De Jesus and 
colleagues found a lower daily pill burden with the single 
tablet regimen of TDF/FTC/EFV (n = 157) or TDF/FTC + 
EFV (2 tablets/day, n = 162) compared to TDF + FTC + EFV   
(3 tablets/day, n = 238) (P = 0.0005 and 0.0262, respectively).12 
In developed countries, preferred initial regimens containing 
the ritonavir-boosted protease inhibitors, atazanavir (ATV/r) 
and darunavir (DRV/r), represent once-daily options, in 
addition to once-daily non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based regimens.1
Reduction in pill burden may also improve adherence 
and outcome, even with regimens that are already dosed 
once-daily. The recent ADONE (ADherence to ONE 
pill) study, a prospective, multicenter study in which 212 
patients on suppressive once-daily regimens containing 
TDF, EFV plus either FTC or 3TC, were switched to the 
single-tablet regimen of FTC/TDF/EFV .13 Reducing the pill 
burden from three or two pills to one pill per day resulted in 
improved adherence (to 96.1% from 93.8%; P , 0.01), which 
continued through 6 months of treatment (96.2%). Quality of 
life improved from 68.8% to 72.7% (P = 0.042).
Dosing frequency and pill burden have also been 
  identified as important treatment characteristics for treat-
ment   persistence.14 Distinct from but related to medication 
  adherence, persistence reflects the duration of time from ini-
tiation to discontinuation of therapy, and can be   measured at 
the regimen or patient level. In developed countries, improved 
regimen persistence, or durability, has been observed with 
regimens dosed once-daily and containing fewer pills.15 In 
general, NNRTI-based regimens (versus PI- and ritonavir Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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[RTV] boosted PI [PI/r]-based regimens), and newer non-
thymidine analog NRTIs TDF and AB  C have   demonstrated 
improved regimen persistence when compared with boosted 
or unboosted PIs, thymidine nucleoside NRTIs (ZDV and 
d4T) and didanosine (ddI). This is likely to be due both to the 
availability of these agents as components of  fixed-dose com-
binations dosed once-daily, and to their improved tolerability 
and toxicity profiles.16 Not surprisingly, the use of FDCs has 
also been associated with a lower frequency of differential 
adherence among their constituent medications compared 
with regimen components administered separately.16 Among 
PIs, the once-daily boosted-PIs ATV/r and DRV/r have shown 
improved persistence attributable to fewer toxicity driven 
regimen switches with these agents compare to other RTV-
boosted PI regimens.17
Intermittent antiretroviral therapy
There was hope that intermittent antiretroviral therapy 
might decrease side effects and toxicity while maintaining 
virologic suppression. Intermittent strategies have included 
interruption and re-initiation of ART determined by either 
pre-specified CD4 thresholds or time intervals. Early pilot 
studies of short-cycle structured treatment interruption (STI) 
used cycles of 7 days on therapy followed by 7 days off. 
In the first pilot study, 10 participants were given d4T, 3TC, 
and ritonavir-boosted indinavir (IDV/r) for up to 68 weeks.18 
While viral rebound (.50 copies/mL) occurred during the 
off-treatment periods, no resistance was detected, there were 
no changes in CD4 cell counts, and lipids levels declined 
significantly. In a subsequent study of 7-day on/off cycles 
of therapy with an EFV-based regimen, 7 of 8 participants 
maintained virologic suppression for 60–84 weeks.19 The 
Five on, Two Off (FOTO) study used a shorter cycle of 5 days 
on and 2 days off therapy.20,21 Thirty subjects were enrolled, 
10 on EFV-based regimens, 10 on NVP-based regimens and 
10 on PI-based regimens. At 24 weeks, as-treated analysis 
showed that virologic suppression was maintained in 26 
of 29 subjects (89.6%). None of the EFV-treated subjects 
developed virologic failure, which was attributed to the long 
half-life of EFV . In addition, patients maintained virologic 
suppression through week 48. No virologic failures were 
noted in either arm.
Three clinical trials (Trivacan, Staccato, and SMART) 
evaluated the safety and efficacy of intermittent therapy 
using a CD4-guided approach. The French-funded Trivacan 
ANRS 1269 trial enrolled 386 HIV-infected adults from Côte 
d’Ivoire.22 Participants were randomized to receive continu-
ous therapy (CT) or CD4-guided therapy as the intermittent 
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regimen (IT), with therapy interruption and re-initiation 
thresholds of 350 and 250 cells/mm3, respectively. Primary 
endpoints were severe AIDS-related morbidity and death. 
The incidence of severe morbidity per 100 person-years was 
higher in the IT group (17.6) compared to the CT group (6.7; 
P , 0.01), with the most frequent event being invasive bacte-
rial infections. This difference led to premature termination 
of the study. There was no statistically significant difference 
in mortality. In the Staccato Trial, CD4-guided treatment 
interruptions were evaluated in participants from Thailand, 
Switzerland and Australia.23 Four hundred and thirty par-
ticipants with CD4 counts greater than 350 cells/mm3 and 
HIV RNA , 50 copies/mL were randomized to continued 
antiretroviral therapy (CT) or scheduled IT. Therapy was 
restarted after a confirmed CD4 count below 350 cells/mm3 in 
the IT arm. The primary study endpoints were the proportion 
of participants with HIV RNA , 50 copies/mL at the end of 
the trial and cumulative ART use in both groups. Reduced 
medication use in the IT group, indicated as a “drug savings” 
compared to the CT group of 61.5%, was reported. HIV RNA 
levels were below 50 copies/mL in 90.5% and 91.8% of the 
participants in the IT and CT groups, respectively. At the end 
of trial, the IT group had lower mean CD4 counts compared 
to the CT group (P , 0.01), and fewer subjects maintained 
a CD4 cell count above 350 cells/mm3 in the IT versus the 
CT group (P , 0.0001). The investigators concluded that a 
substantial drug savings occurred in the IT group, and that 
treatment-related adverse events were more common in the 
CT group.
The SMART study enrolled 5472 patients with CD4 
counts . 350 cells/mm3, randomized to continuous or epi-
sodic ART (CT or IT).24–28 Participants in the IT group deferred 
therapy until the CD4 cell count was ,250 cells/mm3. After 
an average follow-up of 16 months, opportunistic infections 
or death from any cause occurred in 120 IT participants (3.3 
events per 100 person-years) compared with 47 in the CT 
group (1.3 events per 100 person-years), giving a hazard ratio 
of 2.6 (P , 0.001) for the IT group. The trial was stopped 
prematurely, and the investigators concluded that intermittent 
ART increased the risk of opportunistic diseases and death. 
Of note, an unexpected finding was that the incidence of 
cardiovascular, renal and hepatic disease was higher in the IT 
group, whereas it was assumed that ART would increase the 
risk of such adverse outcomes. More recently, observational 
data from the Swiss cohort study26 showed that interruption 
of ART limits CD4 cell recovery and increases the risk for 
opportunistic complications and death. In this study, persons 
receiving continuous ART experienced greater CD4 cell 
recovery and a reduced risk for opportunistic complications 
and death. CD4 cell recovery was less pronounced in persons 
with treatment interruptions more than 6 months.
Therefore, CD4-guided treatment interruption is not a 
recommended strategy, based largely on the greater risk of 
CD4 decline, morbidity, and mortality observed in several 
clinical studies. Results have been more favorable with 
shorter interruptions based on pre-specified time intervals, 
such as the FOTO approach, but this strategy has only been 
studied in small pilot trials. Based on the available evidence, 
intermittent therapy strategies are not recommended.
Induction-maintenance strategies
While earlier studies involving switches from standard 
therapy to less active maintenance regimens failed,29,30 studies 
involving maintenance with triple-NRTI therapy (ZDV/3TC/
ABC) following induction with standard regimens demon-
strated some promise, although with inconsistent results.31–37 
The availability of potent, ritonavir-boosted PIs with better 
safety profiles has renewed interest in induction-maintenance 
approaches. The potential advantages of such ART simplifica-
tion strategy include low pill burden, once-daily dosing, pres-
ervation of future options, avoidance of NRTI-based toxicity 
and lower cost. However, disadvantages include the possibility 
of lower potency, increased likelihood of treatment failure, 
especially with missed doses, lack of penetration into sanctu-
ary sites (central nervous system, genital secretions), and the 
possible need for more frequent virologic monitoring.2
Until recently most of the trials of PI/r monotherapy have 
studied LPV/r. In a systematic review of 22 studies   (including 
6 randomized controlled trials) assessing the efficacy of PI/r 
monotherapy demonstrated slightly inferior efficacy of LPV/r 
monotherapy compared to standard treatment with LPV/r plus 
two NRTIs.38 One of these studies, the OK trial, evaluated 
maintenance with LPV/r monotherapy versus continuing LPV/r 
plus two NRTIs in HIV-infected patients with suppressed HIV 
replication.39,40 This was a randomized, controlled, open-label, 
multicenter, pilot trial. Adult patients were eligible if they 
had no history of virologic failure while receiving a PI, were 
receiving two NRTIs plus LPV/r (400/100 mg twice daily) 
for .1 month and had maintained an HIV RNA , 50 copies/
mL for .6 months prior to enrollment. Forty-two patients 
were randomly assigned 1:1 to continue or stop the NRTIs. At 
baseline there were no significant differences between groups 
in median CD4 count (baseline or nadir), pre-ART viremia, 
or time with HIV RNA , 50 copies/mL prior to enrollment. 
After 48 weeks the percentage of patients maintaining virologic 
suppression by intention to treat (ITT) analysis was 81% for Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the monotherapy group versus 95% for the triple-therapy 
group (P = 0.34). Patients in whom monotherapy failed had 
significantly worse adherence than patients who remained viro-
logically suppressed on monotherapy. Failure of monotherapy 
was not associated with emergence of PI resistance mutations, 
and patients were successfully re-suppressed with addition 
of pre-randomization NRTIs. Mean change in CD4 count 
was +70 cells/mm3 (monotherapy) and +8 cells/mm3 (triple 
therapy) (P = 0.27). Mean serum fasting lipids remained stable 
in both groups. No serious adverse events were observed. At 
96 weeks LPV/r monotherapy – with reintroduction of NRTIs as 
needed – was noninferior to   continuation of triple therapy. The 
incidence of adverse events leading to treatment discontinuation 
was significantly lower with monotherapy.
ACTG 5201 was a non-controlled pilot study (n = 36) 
that evaluated simplified maintenance therapy with ATV/r 
alone in virologically suppressed patients.41,42 Thirty-four 
patients were included in the analysis of the primary end 
point after 24 weeks. 91% did experience virologic success 
(absence of failure) through 24 weeks of simplified therapy. 
Resistance testing at failure did not identify PI resistance 
mutations. While promising, these data need confirmation 
in larger, randomized trials.
More recently, the MONET43 and MONOI44 trials provided 
data using DRV/r monotherapy. In MONET 256 patients with 
HIV RNA , 50 copies/mL for over 24 weeks on current ART 
(NNRTI-based [43%] or PI-based [57%]), switched to DRV/r 
800/100 mg once daily, either as monotherapy (n = 127) or 
with two NRTIs (n = 129). Treatment failure was defined as 
two consecutive HIV RNA levels above 50 copies/mL by 
week 48, or switches off study treatment. DRV/r monotherapy 
was noninferior to continued triple therapy by time to loss 
of virologic response (TLOVR)   analysis.43 MONOI was a 
prospective, open-label, non-inferiority, 96-week safety and 
efficacy trial in virologically suppressed patients on triple 
therapy who were randomized to a DRV/r triple drug regi-
men or DRV/r monotherapy (n = 225).44 In the per protocol 
analysis, treatment success was 99% on DRV/r triple drug 
versus 94% on DRV/r monotherapy; similar results were 
found in intent-to-treat analysis. Only 3 patients experienced 
virologic failure on DRV/monotherapy and none on triple 
therapy. No PI resistance emerged in patients with plasma 
viral load .50 c/mL. DRV/r monotherapy exhibited an 
efficacy rate of over 85%, with concordant results in the 
intent-to-treat and per protocol analyses with respect to the 
magnitude of difference between arms, but discordant con-
clusions with respect to the noninferiority margin. Of note, 
patients failing DRV/r monotherapy had no emergence of new 
DRV resistance mutations. Despite these promising results, 
the use of maintenance PI/r monotherapy after   induction with 
standard ART remains controversial and investigational due 
the lack of definitive data and concerns about the overall long-
term likelihood of treatment failure, especially with missed 
doses, concern about penetration into sanctuary sites (central 
nervous system, genital secretions),41 and the possible need 
for more frequent virologic monitoring.38
Drug substitution or switch  
strategies
Since the early years of the HAART era, ART toxicity and 
tolerability have been identified as the principal causes of 
treatment substitutions, switches, and interruptions.39,40 In 
addition to short-term side effects (eg, GI intolerance, skin 
rash, CNS symptoms) and toxicity (eg, bone marrow suppres-
sion), which have been implicated as causes of poor regimen 
persistence and efficacy,14,45,46 adverse events such as lactic 
acidosis, hepatitis, pancreatitis and longer-term toxicities 
(eg, peripheral neuropathy, lipodystrophy) have been major 
drivers of changes to patients’ ART regimens. Thymidine and 
adenosine analog NRTIs, such as ZDV , d4T and ddI, have 
been implicated as the cause of many of these toxicities, 
which have required treatment changes,14,17 and which may 
have been compounded by lower body weight, as recently 
observed in a resource-limited setting.15,17
In-class switches
In patients with moderate to severe lipoatrophy, signifi-
cant increases in subcutaneous fat were observed over 104 
weeks after switching from a thymidine analog to TDF or 
ABC.47 Substitution of  ZDV or d4T for TDF has led to partial 
reversal of  lipoatrophy.47 Individuals receiving ZDV/3TC in 
the SWEET study who were randomized to switch to TDF/
FTC experienced significant improvement in lipoatrophy 
measured by limb fat on dual-energy X-ray absorptiometry 
(DEXA) scan at 48 weeks, and also reported fewer adverse 
events related to mitochondrial toxicity than individuals 
continuing ZDV/3TC.48 In addition, other reasons for in-class 
switches might include peripheral neuropathy (d4T to other 
NRTI)49,50 or CNS side-effects (EFV to nevirapine [NVP]51 or 
etravirine [ETR]).52 In a trial reported by Waters and colleagues, 
switching from EFV to ETR led to a significant reduction 
in overall CNS adverse events such as insomnia, abnormal 
dreams and nervousness. Lack of  improvement for some events 
suggests other causative   factors.52 ARV-related gastrointesti-
nal side effects can also be a reason for in-class switch (eg, 
LPV/r to ATV/r or DRV/r, AZT to other NRTI).45,53,54 Finally, Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the SWAN study, in which there was a switch from a stable 
PI-based to an ATV-based regimen, demonstrated significant 
improvements in lipids after switch.55
Out-of-class switches
In treatment experienced patients on a stable suppressive 
enfuvirtide (ENF)-containing regimen, raltegravir (RAL) has 
been safely substituted for ENF.56,57 The SWITCHMRK-1 
and -2 studies randomized 707 patients on a suppressive LPV/r-
based regimen to switch from LPV/r to RAL or to remain on 
LPV/r, while continuing background therapy consisting of at 
least two NRTIs. The switch was associated with more viro-
logic failure than continued therapy with LPV/r.58 In contrast, 
SPIRAL was a 48-week Spanish open label trial with similar 
study design but different results (n = 273). In patients with sus-
tained virological suppression on PI/r-based therapy, switching 
from a PI/r to RAL demonstrated noninferior efficacy compared 
to continued PI/r-based therapy, with improvement in lipid 
profile at 48 weeks.59 Also, in the ODIS trial (n = 222),60 sup-
pressed patients (HIV RNA , 50 copies/mL for .24 weeks) 
were randomly assigned to RAL 800 mg QD, 400 mg BID, 
or 400 mg BID for the first 3 months then 800 mg QD. There 
were no significant differences when comparing RAL twice 
daily to once daily. The reason for the difference in outcome in 
these trials is unclear. It is possible that the other agents used 
in combination with RAL had greater activity in SPIRAL than 
they did in SWITCHMRK. It has also been suggested that 
the difference might be accounted for by the longer period of 
virologic suppression before switch in SPIRAL.
When considering treatment switches to improve   tolerability 
and/or reduce toxicity, dosing frequency or pill burden, it is 
critical to consider the potential for untoward   consequences 
related to virologic efficacy and sustained viral load suppres-
sion. Depending upon the activity of the other agents in a 
combination regimen, it may be ill-advised to switch from an 
antiretroviral medication with a high genetic barrier to a resis-
tance to one with a lower resistance   barrier (eg, from a PI/r to 
RAL or an NNRTI). In the setting of a background regimen 
with reduced antiviral activity, a switch to an agent with a low 
genetic barrier could result in viral rebound with the emergence 
of resistance. In contrast, switching to drugs with comparable 
or higher genetic barriers is generally felt to be safe, contingent 
upon the full activity of such agents.
Simplified ART regimen, adherence,  
and health care cost
In developed countries, ART simplification often increases 
cost, as shown in a US study demonstrating that better 
ART adherence was associated with decreased health care 
  utilization but increased total costs because of the higher cost 
of ART (60% of total costs)61 compared to other patient-related 
direct costs (hospitalization, laboratory, clinic visits, etc). 
The exception is PI/r monotherapy and intermittent therapy, 
neither of which is recommended. Cost has also influenced 
treatment recommendations. For example, in the UK it is now 
recommended that ABC be prescribed preferentially over TDF, 
and that ATV/r is the preferred PI-based regimen in order to 
reduce costs to the National Health Service.62 In the US, with 
the growth of AIDS Drug Assistance Programs (ADAP) wait-
ing lists and the impending availability of generic versions 
of preferred antiretroviral medications, there is potential for 
a paradoxical “de-simplification” of ART, with movement 
away from fixed-dose, lower pill burden regimens, to reduce 
the cost of ART. There may be a requirement from third-party 
payers to use generic, non-coformulated agents rather than 
newer agents or fixed-dose combinations.63
The situation in developing countries is somewhat different 
because of the availability of numerous generic coformulated 
products and name-brand drugs at lower   negotiated prices. The 
generic coformulation of d4T/3TC/NVP is commonly used 
in sub-Saharan Africa, has been show to be highly effective, 
and costs about $20 per patient per month.5,49 In such settings, 
single-tablet, fixed-dose combinations improve the reliability 
and security of supplies, reduce the number of pills, simplify 
the dosing regimen, are easier to take, enhance adherence, 
reduce the potential for inappropriate sharing of drugs, ensure 
that the correct dosage of each component is taken.64
Following the 2010 World Health Organization (WHO) 
ART recommendations,3 d4T has been progressively phased out 
as a prefered first-line regimen in resource-limited settings and 
replaced by TDF, which has a better toxicity profile,45,65,66 thus 
requiring fewer treatment switches compared to AZT45 or d4T.65 
A generic version of TDF has been registered and is available in 
some parts of Africa such as South Africa, Zambia, Botswana 
and Namibia. Until recently, the availability of TDF in the public 
sector in South Africa has generally been limited by the high 
costs of the drug.67 However, following an agreement with the 
Clinton Foundation HIV/AIDS Initiative (CHAI), Matrix Labo-
ratories, an Indian-based generics manufacturer, has committed 
to market TDF-based FDCs at prices that are competitive with 
South Africa’s first line d4T-based regimens. TDF-based FDCs 
marketed through the CHAI agreement cost less than the most 
commonly used first line regimen of d4T + 3TC + EFV . While 
the cost is still slightly higher than the cost of d4T + 3TC + NVP, 
less than 30% of patients are on this regimen. The cost per 
patient per month of first line-regimens in the public sector for Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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d4T + 3TC + EFV is US$22; for d4T + 3TC + NVP is US$11. 
The costs of TDF-containing FDCs procured through CHAI 
are US$17.50 for TDF/3TC/EFV and US$19.92 for TDF/
FTC/EFV .67 The 2010 South African Department of Health 
ARVs guidelines recommends that all new HIV-infected adult   
patients eligible for treatment (including pregnant women) be 
started on TDC + either 3TC or FTC + either EFV or NVP. 
Those who are already on d4T and tolerating it should remain 
on that drug unless they are at risk for complications (high 
BMI, low hemoglobin, older female).68
If TDF-based FDCs are produced at sufficient   volumes, 
they can be produced and marketed at prices that are 
  competitive with d4T-based regimens. South Africa is the 
largest ARV provider in the world and would therefore meet 
the volumes required by generic companies to produce and 
market TDF-based FDCs at competitive prices. It has been 
shown by Rosen and colleagues that TDF at the price of 
US$17 per month in South Africa could substantially save 
on d4T toxicity management and offset roughly 20% of the 
higher price of TDF. However, further decrease in TDF cost 
would be needed to make it highly cost-effective.69
Conclusion
High rates of sustained virologic suppression have been 
achieved with modern ART regimens, with increased atten-
tion on between-regimen differences (pill burden, dosing 
frequency, tolerability and toxicity) as principal determinants 
of enduring treatment success. Improved treatment adherence 
and regimen persistence have been observed with once-daily, 
low pill burden regimens, largely as a function of the improved 
tolerability and better toxicity profile of such regimens, 
many of which include co-formulated antiretroviral agents. 
Intermittent ART strategies are not recommended, and there 
is insufficient evidence to support induction-maintenance 
approaches. The role of regimen simplification using drugs 
with better toxicity profiles and lower pill burdens and issues 
related to quality of life, drug cost and cost-effectiveness have 
important implications not only for individual patients, but 
also for health care policy, guidelines and programmatic 
implementation and ART distribution globally.
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